Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax Ointment; Co-Promotion Agreements on Zovirax Cream and Cordran Tape

Fri Apr 5, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130405:nPnNY89339


PARSIPPANY, N.J.  and  MONTREAL, QUEBEC,  April 5, 2013  /PRNewswire/ --
Actavis, Inc. (NYSE: ACT), and Valeant Pharmaceuticals International, Inc.
(NYSE: VRX) (TSX: VRX) today announced that they have entered into an agreement,
effective immediately, for Actavis to be the exclusive marketer and distributor
of an authorized generic of Valeant's Zovirax ointment (acyclovir 5%) product. 
Additionally, Valeant has granted Actavis the exclusive right to co-promote
Zovirax cream (acyclovir 5%) to obstetricians and gynecologists in the U.S., and
Actavis has granted Valeant the exclusive right to co-promote Actavis Specialty
Brands' Cordran Tape (flurandrenolide) product in the U.S.

(Logo:  http://photos.prnewswire.com/prnh/20130124/NY47381LOGO)

Zovirax Authorized Generic Agreement
Under the terms of the exclusive Zovirax ointment agreement, Valeant will supply
Actavis with a generic version of Valeant's Zovirax ointment product and Actavis
will market and distribute the product in  the United States. Actavis will
record all of the net sales of the generic ointment product and Valeant will
receive a share of the economics. Other terms of the agreement have not been
disclosed.  

Zovirax  Cream and Cordran  Tape Co-Promotion Agreements
Under terms of the agreement related to the co-promotion of Zovirax cream,
Actavis will utilize its existing Specialty Brands sales and marketing structure
to promote the product and will receive a co-promotion fee from sales generated
by prescriptions written by its defined targeted physician group.  Under the
terms of the Cordran Tape co-promotion agreement, Valeant will utilize its
existing Dermatology sales and marketing structure to promote the product, and
will receive a co-promotion fee on sales.  Each party will retain all rights in
and to its respective products and trademarks including booking of sales. Other
terms of the agreement have not been disclosed.

Zovirax cream 5% is indicated for the treatment of recurrent herpes labialis
(cold sores) in adults and adolescents (12 years of age and older). Zovirax
ointment 5% is indicated in the management of initial genital herpes and in
limited non-life-threatening mucocutaneous herpes simplex virus infections in
immunocompromised patients.   

Cordran Tape, a potent  corticosteroid  for topical use, is a transparent,
waterproof medicated tape used to treat the inflammation and itching caused by a
number of skin conditions such as allergic reactions, eczema and psoriasis.  

About Actavis, Inc.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand and
biosimilar products.  The Company has global and U.S. headquarters in 
Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.
  

Actavis is the world's third-largest generics prescription drug manufacturer. 
Operating as Actavis Pharma, the Company develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries.  The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.
  Actavis Pharma also develops and out-licenses generic pharmaceutical products
outside the U.S. through its Medis third-party business, the world's largest
generic pharmaceutical out-licensing business. Medis has more than 300 customers
globally, and offers a broad portfolio of more than 200 products.   

Actavis Specialty Brands is the Company's global branded specialty
pharmaceutical business, which develops and markets a portfolio of approximately
40 products principally in  the United States  and  Canada  that are focused in
the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands
is committed to developing and marketing biosimilars products in Women's Health,
Oncology and other therapeutic categories, and currently has a portfolio of 5
biosimilar products in development.   

Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, with a capacity of approximately 44 billion units
annually.  Actavis Global Operations also includes Anda, Inc., the
fourth-largest U.S. generic pharmaceutical product distributor in  the United
States.

For press release and other company information, visit Actavis' Web site at 
http://www.actavis.com.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational
specialty pharmaceutical company that develops, manufactures and markets a broad
range of pharmaceutical products primarily in the areas of dermatology,
neurology,  and branded generics. More information about Valeant Pharmaceuticals
International, Inc. can be found at  www.valeant.com.  

Actavis Forward-Looking Statement  

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual performance.
Actual results may differ materially from Actavis' current expectations
depending upon a number of factors affecting Actavis' business. These factors
include, among others, the inherent uncertainty associated with financial
projections; the difficulty of predicting the timing or outcome of FDA approvals
or actions, if any; the impact of competitive products and pricing; the timing
and success of product launches; difficulties or delays in manufacturing; the
availability and pricing of third party sourced products and materials;
successful compliance with FDA and other governmental regulations applicable to
Actavis and its third party manufacturers' facilities, products and/or
businesses; and such other risks and uncertainties detailed in Actavis' periodic
public filings with the Securities and Exchange Commission, including but not
limited to Actavis' annual report on Form 10-K for the year ended  December
31,2012. Except as expressly required by law, Actavis disclaims any intent or
obligation to update these forward-looking statements.  

Valeant Forward-Looking Statement



This press release contains forward-looking statements regarding, among other
things, the future supply, marketing, promotion and distribution of products. 
Statements including words such as "believes," "expects," "anticipates,"
"intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar
expressions are forward-looking statements.  Because these statements reflect
Valeant's current views, expectations and beliefs concerning future events,
these forward-looking statements involve risks and uncertainties. Investors
should note that many factors could cause actual results to differ materially
from those expressed in forward-looking statements contained in this press
release. These factors include, but are not limited to the market acceptance of
products and other risks and uncertainties, including those detailed from time
to time in Valeant's periodic reports filed with the Securities and Exchange
Commission ("SEC") and the Canadian Securities Administrators ("CSA"), including
current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on
Form 10-K, particularly the discussion under the caption "RISK FACTORS" in
Valeant's annual report on Form 10-K for the year ended  December 31, 2012,
which have been filed with the SEC and the CSA. The forward-looking statements
in this press release are qualified by these risk factors. These are factors
that, individually or in the aggregate, could cause Valeant's actual results to
differ materially from expected and historical results. Valeant assumes no
obligation to publicly update any forward-looking statements, whether as a
result of new information, future developments or otherwise.







Actavis:
Investors:
Lisa DeFrancesco
(862) 261-7152



Media:
Charlie Mayr
(862) 261-8030



Valeant:
Laurie W. Little
(949) 461-6002

SOURCE  Actavis, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.